Your new post is loading...
XBiotech has developed the anti-IL-1 alpha antibody MABp1 antibody therapies for cancer, psoriasis, acne, cardiovascular disease is in Phase III clinical trials for these biopharmaceutics for antibody therapy.
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Scoop.it!
Via Krishan Maggon
FDA fast track for CRC and vascular disease mabs.
XBiotech intends to launch its first anti-infective therapy targeting methicilin resistant staphylococcus aureus (MRSA) before the end of 2014. XBiotech is also leveraging its manufacturing technology to develop ultra-low-cost biosimilar drugs. The lead molecule in this program is a "biobetter," which is expected to define a new market for the supportive care product G-CSF.